All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Ipsen Biopharmaceuticals, Lilly, and Pfizer. View funders.
Bookmark this article
This year’s American Association for Cancer Research (AACR) annual meeting took place on 1–5 April in Washington, DC, USA. The program committee Chair was Kornelia Polyak, MD, PhD, from the Dana-Farber Cancer Institute, Boston, Massachusetts.
On Monday 3rd April, a poster (1479 / 21) by Katerina Musilova, from Ceitec MU, Faculty of Medicine MU, and University Hospital Brno, Czech Republic, et al. titled “Differential expression of microRNAs in transformation of follicular lymphoma to diffuse large B cell lymphoma” was presented.
The group explored the role of miRNAs in the transformation of indolent FL into aggressive DLBCL; transformation occurs in around 3% of cases per year and has a median survival of only 2 years.
The poster was concluded by stating that expression of miR-150 reduced during transformation of FL to DLBCL; low miR-150 expression correlated with high FLIPI score and Ki67 levels. The group are conducting additional investigations exploring to what extent miR-150 expression reduction is causally responsible for aggressiveness/transformation of FL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox